Premature-early menopause in women with MVP increased arrhythmic risk nearly 4-fold (OR 3.97) and 4-fold higher cardiovascular events risk without MHT (HR 4.10).
Does premature or early menopause increase the risk of ventricular arrhythmias and adverse cardiovascular outcomes in women with mitral valve prolapse?
Premature or early menopause in women with mitral valve prolapse is associated with a nearly four-fold increased risk of arrhythmic presentation and adverse cardiovascular outcomes, suggesting menopausal age is a key risk stratification factor.
Absolute Event Rate: 0% vs 0%
Background Women with mitral valve prolapse (MVP) may have a higher risk of ventricular arrhythmias (VAs) and sudden cardiac death (SCD), but the impact of menopausal age remains unclear. This study examined the association between menopausal age, arrhythmic risk, and cardiovascular outcomes in women with MVP. Methods We included 299 female patients with MVP (mean age 58 ± 17 years) and clinical, echocardiographic, and ECG data. Menopausal status was classified as premature (<40 years), early (40-45 years), expected age (45-55 years), undetermined age, or pre/perimenopausal. Arrhythmic MVP was defined by a composite of SCD or arrest, ventricular fibrillation (VF)/tachycardia, or frequent ventricular ectopy. The study composite endpoint included cardiovascular death, heart failure hospitalization, or mitral valve intervention. Results Among postmenopausal women (69.2%), 3.8% had premature, 6.2% early, 49.5% expected-age, and 18.4% undetermined-age menopause. Menopausal hormone therapy (MHT) use was reported in 16.4% of postmenopausal women. There was a higher prevalence of arrhythmic MVP among women with premature-early menopause (52%) compared to other groups ( P = .01). After multivariable adjustment, premature-early menopause remained significantly associated with an increased arrhythmic risk (OR, 3.97; 95% confidence interval CI, 1.33-11.8). During a mean follow-up of 4.7 ± 3.1 years, 53 composite events occurred. Premature-early menopause without MHT was associated with an increased risk of the composite of cardiovascular events (HR, 4.10; 95% CI, 1.41-11.9). Conclusions Premature or early menopause in women with MVP was associated with an increased risk of arrhythmic presentation and adverse cardiovascular outcomes during follow-up. Menopausal age may serve as an additional risk stratification factor in women with MVP.
Tastet et al. (Fri,) reported a other. Premature-early menopause in women with MVP increased arrhythmic risk nearly 4-fold (OR 3.97) and 4-fold higher cardiovascular events risk without MHT (HR 4.10).